We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AbbVie (ABBV) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of AbbVie (ABBV - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ABBV and the rest of the Medical group's stocks.
AbbVie is a member of our Medical group, which includes 904 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ABBV is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ABBV's full-year earnings has moved 0.11% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ABBV has gained about 12.21% so far this year. In comparison, Medical companies have returned an average of 1.18%. This means that AbbVie is outperforming the sector as a whole this year.
Looking more specifically, ABBV belongs to the Large Cap Pharmaceuticals industry, a group that includes 15 individual stocks and currently sits at #29 in the Zacks Industry Rank. This group has gained an average of 0.56% so far this year, so ABBV is performing better in this area.
ABBV will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is AbbVie (ABBV) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of AbbVie (ABBV - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ABBV and the rest of the Medical group's stocks.
AbbVie is a member of our Medical group, which includes 904 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ABBV is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ABBV's full-year earnings has moved 0.11% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ABBV has gained about 12.21% so far this year. In comparison, Medical companies have returned an average of 1.18%. This means that AbbVie is outperforming the sector as a whole this year.
Looking more specifically, ABBV belongs to the Large Cap Pharmaceuticals industry, a group that includes 15 individual stocks and currently sits at #29 in the Zacks Industry Rank. This group has gained an average of 0.56% so far this year, so ABBV is performing better in this area.
ABBV will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.